Northwestern University Feinberg School of Medicine

Paul Burridge Lab

News

Read the latest news from the Burridge Lab. The links below take you to articles where you can learn more about our lab’s latest achievements, awards, and honors.

News

  • Two Postdoctoral Positions Available
    10/08/2020

    Two Postdoctoral Fellow Positions Available - Large-Scale iPSC Culture, Cultivated Meat

    Two postdoctoral fellow positions are available in the laboratory of Dr. Paul Burridge in the Department of Pharmacology at Northwestern University Feinberg School of Medicine, Chicago, IL.

    The Burridge Lab is one of the world leaders in chemically defined and cost-effective iPSC generation, culture, and differentiation. 

    Successful candidates will be involved in projects involving:

    • Non-integrating, chemically defined non-human iPSC reprogramming 
    • Cost-effective, chemically defined non-human iPSC culture 
    • Human and non-human chemically defined skeletal muscle differentiation
    • Development of very large scale automated bioreactor-based human cardiac, and human and non-human skeletal muscle differentiation

    Desirable expertise includes: iPSC reprogramming (human, bovine, and porcine), iPSC culture, and differentiation methodologies (cardiac and skeletal muscle); bioreactors; hiPSC disease modeling; bioinformatics.

    Good verbal and written communication skills in English are essential. The successful candidate will join a dynamic research environment in the Department of Pharmacology, which offers both basic science and clinical translational opportunities to explore fundamental questions in pharmacogenomics. More details can be found here: http://labs.feinberg.northwestern.edu/burridge/

    Salary will be according to NIH (NRSA) Scale and commensurate with experience.

    Please send a CV (including publications), a cover letter containing a brief description of research experience and interests, and a list of 2-3 references to:  paul.burridge@northwestern.edu

    Northwestern University is an Equal Opportunity, Affirmative Action Employer of all protected classes, including veterans and individuals with disabilities. Women and minorities are encouraged to apply. Hiring is contingent upon eligibility to work in the United States.

    The positions will remain open until filled. 

  • Davi's review on hiPSC models for chemotherapy-induced toxicity published in Current Cardiology Reports
    06/19/2020

    Pluripotent Stem Cell Modeling of Anticancer Therapy-Induced Cardiotoxicity

    https://pubmed.ncbi.nlm.nih.gov/32562096/

    PDF 

    Abstract

    Purpose of review: In this article, we review the different model systems based on human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and how they have been applied to identify the cardiotoxic effects of anticancer therapies.

    Recent findings: Developments on 2D and 3D culture systems enabled the use of hiPSC-CMs as screening platforms for cardiotoxic effects of anticancer therapies such as anthracyclines, monoclonal antibodies, and tyrosine kinase inhibitors. Combined with computational approaches and higher throughput screening technologies, they have also enabled mechanistic studies and the search for cardioprotective strategies. As the population ages and cancer treatments become more effective, the cardiotoxic effects of anticancer drugs become a bigger problem leading to an increased role of cardio-oncology. In the past decade, human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have become an important platform for preclinical drug tests, elucidating mechanisms of action for drugs, and identifying cardioprotective pathways that could be further explored in the development of combined treatments. In this article, we highlight 2D and 3D model systems based on hiPSC-CMs that have been used to study the cardiotoxic effects of anticancer drugs, investigating their mechanisms of action and the potential for patient-specific prediction. We also present some of the important challenges and opportunities in the field, indicating possible future developments and how they could impact the landscape of cardio-oncology.

    Keywords: Anticancer therapy; Cardio-oncology; Cardiomyocyte; Cardiotoxicity; Chemotherapy; Human induced pluripotent stem cell.

  • Hana and Davi's B8 protocol paper published
    06/01/2020

    Generating a Cost-Effective, Weekend-Free Chemically Defined Human Induced Pluripotent Stem Cell (hiPSC) Culture Medium

    https://pubmed.ncbi.nlm.nih.gov/32463953/

    PDF

    Read more about this protocol in our B8 section

    Abstract

    We have previously developed a cost-effective chemically defined medium formula for weekend-free culture of human induced pluripotent stem cells (hiPSCs), costing ∼3% of the price of commercial medium. This medium, which we termed B8, is specifically optimized for robust and fast growth of hiPSCs and for a weekend-free medium change regimen. We demonstrated that this medium is suitable for reprogramming of somatic cells into hiPSCs and for differentiation into a variety of lineages. Here, we provide a protocol for simple generation of the most cost-effective variant of this medium, along with a protocol for making Matrigel-coated plates and culturing, passaging, cryopreserving, and thawing hiPSCs. © 2020 Wiley Periodicals LLC. Basic Protocol 1: Preparation of a highly optimized, robust, and cost-effective human induced pluripotent stem cell culture medium Basic Protocol 2: Weekend-free maintenance and passaging of human induced pluripotent stem cells in B8 medium.

    Keywords: chemically defined; cost-effective; culture medium; human induced pluripotent stem cells; weekend-free.

     

  • Tarek's paper on Nanopore sequencing published
    03/09/2020

    Precise and Cost-Effective Nanopore Sequencing for Post-GWAS Fine-Mapping and Causal Variant Identification

    https://pubmed.ncbi.nlm.nih.gov/32203907/

    Abstract

    Fine-mapping of interesting loci discovered by genome-wide association study (GWAS) is mandatory to pinpoint causal variants. Traditionally, this fine-mapping is completed through increasing the genotyping density at candidate loci, for which imputation is the current standard approach. Although imputation is a useful technique, it has a number of limitations that impede accuracy. In this work, we describe the development of a precise and cost-effective Nanopore sequencing-based pipeline that provides comprehensive and accurate information at candidate loci to identify potential causal single-nucleotide polymorphisms (SNPs). We demonstrate the utility of this technique via the fine-mapping of a GWAS positive hit comprising a synonymous SNP that is associated with doxorubicin-induced cardiotoxicity. In this work, we provide a proof of principle for the application of Nanopore sequencing in post-GWAS fine-mapping and pinpointing of potential causal SNPs with a minimal cost of just ~$10/100 kb/sample.

    Keywords: Genomic Analysis; Genomics; Omics; Pharmacoinformatics.

  • Review from Emily and Tarek published in JCTR
    02/27/2020

    Our latest review: 

    Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity

    https://link.springer.com/article/10.1007/s12265-020-09962-x

     

     

  1.